E. Robinson
Memorial Sloan Kettering Cancer Center
4 Papers
51 Citations
E. Robinson is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Bevacizumab. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
Yelena Y. Janjigian,D. Werner,Claudia Pauligk,K. Steinmetz,David P. Kelsen,Elke Jäger,H.-M. Altmannsberger,E. Robinson,Laura J. Tafe,Laura H. Tang,Manish A. Shah,Salah-Eddin Al-Batran +11 more
TL;DR: Nearly 20% of Western patients with metastatic gastric cancer are HER2 positive, and multivariate analysis indicated that HER2 status was not an independent prognostic factor of patient outcome in metastatic Gastric or GEJ.
350
Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial
David P. Kelsen,Minaxi Jhawer,D. Ilson,Archie Tse,J. Randazzo,E. Robinson,Marinela Capanu,Manish A. Shah +7 more
TL;DR: Shah et al. as discussed by the authors reported mature tolerability and efficacy results of mDCF+BEV in GE cancer, with an emphasis on prolonged pt survival, and the primary objective was to improve 6-month progression free survival (PFS) from 43% (historical DCF control) to 63% with the addition of BEV.
33
Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.
Manish A. Shah,Yelena Y. Janjigian,Claudia Pauligk,Dominique Werner,D. P. Kelsen,Elke Jaeger,Hans-Michael Altmannsberger,E. Robinson,Laura H. Tang,V. V. Barbashina,Salah-Eddin Al-Batran +10 more
TL;DR: Almost 20% of Western patients with advanced gastric cancer are HER2+.
17
Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.
E. C. Smyth,Peter C. Enzinger,Jia Li,Michele Vincitore,Jill Lacy,B. F. El-Rayes,Pamela L. Kunz,James M. Ford,E. Robinson,David P. Kelsen,Manish A. Shah +10 more
TL;DR: The US experience of Bev with chemotherapy in advanced GC and contrast U.S. phase II trials with Bev differ significantly from the AVAGAST cohort, indicating Bev may be active in some GC subtypes.
5